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Abstract 
Introduction: Type 2 diabetes mellitus (T2DM) promotes adverse myocardial remodelling and 
increased risk of heart failure; effects that can occur independently of hypertension or coronary 
artery disease. As cardiac fibroblasts (CF) are key effectors of myocardial remodelling, we 
investigated whether inherent phenotypic differences exist in CF derived from T2DM donors 
compared with cells from non-diabetic (ND) donors.  
Methods: Cell morphology (cell area), proliferation (cell counting over 7-day period), insulin 
signalling (phospho-Akt and phospho-ERK Western blotting) and mRNA expression of key 
remodelling genes (real-time RT-PCR) were compared in CF cultured from atrial tissue from 14 
ND and 12 T2DM donors undergoing elective coronary artery bypass surgery. 
Results: The major finding was that type I collagen (COL1A1) mRNA levels were significantly 
elevated by 2-fold in cells derived from T2DM donors compared with those from ND donors; 
changes reflected at the protein level. T2DM cells had similar proliferation rates but a greater 
variation in cell size and a trend towards increased cell area compared with ND cells.  Insulin-
induced Akt and ERK phosphorylation were similar in the two cohorts of cells. 
Conclusion: CF from T2DM individuals possess an inherent pro-fibrotic phenotype that may 
help to explain the augmented cardiac fibrosis observed in diabetic patients.   
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Mini Summary 
We investigated whether inherent phenotypic differences exist between cardiac fibroblasts 
cultured from donors with or without Type 2 diabetes. Cell morphology, proliferation, insulin 
signalling and gene expression were compared between multiple cell populations. The major 
finding was that type I collagen levels were elevated in fibroblasts from diabetic donors, which 
may help explain the augmented cardiac fibrosis observed with diabetes.    
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1. Introduction 
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease associated with sedentary 
lifestyles and obesity which manifests as a result of insulin resistance. Currently T2DM affects 
over 250 million people worldwide and its prevalence is predicted to rise significantly over the 
coming years [1]. Overt T2DM is often preceded by several years of insulin resistance during 
which time the pancreas maintains glycaemic control by secreting increased levels of insulin. 
Consequently, diagnosis of T2DM is often made only when pancreatic insulin secretion becomes 
insufficient to maintain normoglycaemia and symptoms of hyperglycaemia ensue. Diabetic 
patients therefore experience long-term metabolic disturbances that can have detrimental effects 
well before diagnosis. T2DM manifests with a heightened inflammatory and pro-fibrotic state 
[2,3] and is an independent risk factor for cardiovascular disease in both men and women [4]. 
The association between T2DM and heart failure occurs irrespective of aetiology (ischaemic or 
non-ischaemic) [5], suggesting that T2DM confers detrimental effects directly on the heart. 
Indeed, WKHWHUPµdiabetic cardiomyopathy¶ is used to describe a pathology that occurs 
independently of coronary artery disease and hypertension, and manifests as increased left 
ventricular mass and reduced ventricular contractility, together with interstitial fibrosis and 
increased diastolic stiffness [6,7]. Although often manifesting as changes in ventricular 
remodelling, T2DM is also strongly associated with atrial fibrillation [8] which can drive 
subsequent atrial remodelling [9]. The cellular and molecular mechanisms underlying the 
heightened inflammatory and fibrotic states associated with T2DMare yet to be fully elucidated.  
 Cardiac fibroblasts (CF) [10] are the most prevalent cell type in the heart. In health they are 
relatively quiescent cells responsible for maintaining cardiac extracellular matrix (ECM) 
homeostasis through regulated collagen and matrix metalloproteinase (MMP) synthesis [10]. In 
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cardiovascular disease, increased mechanical wall stress and biochemical stimuli induce 
phenotypic differentiation of CF into hyper-secretory myofibroblast cells [10-12]. Fibroblasts 
and myofibroblasts regulate many aspects of cardiac pathophysiology, and as well as being 
important for the repair of the heart after injury (e.g. myocardial infarction) they also contribute 
to fibrosis and heart failure progression [10-12]. 
 Despite the significance of CF in regulating cardiac remodelling there is relatively little 
known about whether diabetes can directly modulate CF function. There are several reports 
describing in vitro effects of elevated glucose concentration on CF function [13-16], however 
hyperglycaemia represents only one component of the complex diabetic milieu. Very recent 
evidence from rat and mouse models of T2DM has suggested that there are functional 
differences in CF derived from T2DM hearts compared with control hearts [17,18], however 
there is no current evidence that such differences exist in human CF.  
 The aim of the present study was to determine whether there are phenotypic differences in 
cultured CF derived from T2DM patients compared with cells from donors without diagnosed 
diabetes; differences that may contribute to adverse cardiac remodelling in T2DM individuals. 
Accordingly, we compared cell morphology, cell proliferation, insulin signalling and specific 
gene expression responses in CF derived from a cohort of 14 non-diabetic (ND) and 12 T2DM 
donors.  
 
2. Materials and Methods 
2.1. Cell culture 
CF were isolated and cultured as described previously [19-21] by collagenase digestion of right 
atrial appendage samples from 26 patients without left ventricular dysfunction undergoing 
Sedgwick 
 
6 
 
coronary artery bypass graft surgery at Leeds General Infirmary. Local ethical committee 
approval and informed patient consent were obtained. CF were cultured in full growth medium 
(FGM) comprising 'XOEHFFR¶V 0RGLILHG(DJOH¶V0HGLXP supplemented with 10% foetal calf 
serum (FCS), 100 µg/ml penicillin-streptomycin and 2 mM L-glutamine, as described previously 
[19-21]. Experiments were performed on CF from passages 3-6. Experiments were conducted on 
cells from a total cohort of 14 ND control donors (86% male, mean age 64.8±1.7, range 50-75) 
and 12 T2DM donors (92% male, mean age 68.2±3.1, range 42-83). Of the diabetic individuals, 
5 were receiving oral therapy, 5 were receiving insulin plus oral therapy and 2 were diet-
controlled. 
  
2.2. Cell area calculation 
Images were taken of sub-confluent cell populations from individual ND and T2DM donors (10 
patients per cohort) at x100 magnification under light microscopy using Ulead Photo Explorer 
7.0. Outlines of the first 50 cells per donor were drawn using Image J software 
(http://imagej.nih.gov/ij) and cell areas calculated and averaged from the number of 
encompassed pixels before conversion to Pm2.  
 
2.3. Proliferation assays 
Proliferation assays were conducted as described previously [20]. Briefly, cells from ND and 
T2DM donors (8 patients per cohort) were plated at 1x104 cells per well in 1 ml FGM and 
incubated overnight prior to being growth-arrested in serum-free medium (SFM) for 72 h. FGM 
was refreshed on days 0, 2, 4 and 7 and quadruplicate cell counts were conducted using a 
haemocytometer and Trypan Blue.  
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2.4. Western blotting 
Serum-starved cells from 5 ND and 5 T2DM donors were incubated with 100 nM insulin for 5-
60 min before preparing whole cell homogenates by scraping the cell layer into SDS-PAGE 
sample buffer supplemented with phosphatase and protease inhibitors [22]. Equal protein 
concentrations of samples (typically 10 µg/lane) were resolved by SDS-PAGE prior to Western 
blotting with primary antibodies (Cell Signaling Technology) for phospho-Akt(Ser-473) or 
phospho-ERK(Thr-202/Tyr-204) [22]. Densitometric analysis was performed using Image J 
software and data expressed relative to a loading control included on each gel.   
 For assessment of type I collagen protein levels, equal protein concentrations (10 µg) of 
control samples from signalling experiments were resolved on the same gel before probing 
membranes with anti-COL1A1 antibody (sc-8784; Santa Cruz Biotechnology). Membranes were 
reprobed with anti-ȕ-actin antibody (ab8226; Abcam) as a loading control, and densitometric 
data expressed as the ratio of type I collagen to ȕ-actin levels.  
 
2.5. Quantitative real time-PCR 
Serum-starved cells from 6 ND and 6 T2DM donors were incubated with low-serum medium 
(SFM supplemented with 0.4% FCS) containing 10 ng/ml interleukin (IL)-1D for 6-24 h. This 
concentration of IL-1D was selected based on our previous study of cytokine gene expression in 
human CF [23]. RNA extraction and reverse transcription was performed as described previously 
[24]. Real-time PCR was performed in triplicate using the Applied Biosystems ABI-7500 
System and Taqman primer/probes for ,/ȕ (Hs00174097_m1 primer/probe set), IL6 
(Hs00174131_m1), IL8 (Hs99999034_m1), COL1A1 (Hs00164004_m1), ACTA2 
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(Hs00426835_g1), MMP2 (Hs01548727_m1) and MMP3 (Hs00233962_m1). Data are 
expressed relative to GAPDH mRNA expression (Hs99999905_m1) using the formula 2-ǻ&7x100 
[24]. 
 
2.6. Statistical analysis 
Results are presented as mean ± standard error, and the number of experiments on cells from 
different patients is represented by n. Data were analysed with GraphPad Prism 6 software using 
Student t-tests or two-way ANOVA with Holm-6LGDN¶Vpost-hoc test, as appropriate. P<0.05 was 
considered statistically significant.  
 
3. Results 
3.1. Influence of T2DM on cell morphology 
We investigated whether there was an association between diabetic status and cellular 
morphology in CF cultured from multiple ND and T2DM donors. Mean spread cell areas were 
calculated from 50 cells per patient, with representative images shown in Fig. 1A. The combined 
data showed that there was more variation in cell size in the T2DM group compared with ND 
controls (Fig. 1B). Moreover, there was a strong trend towards increased cell size in cells from 
T2DM donors compared with ND (Fig. 1B), although this did not quite reach statistical 
significance (P=0.079).  
 
3.2. Influence of T2DM on proliferation rate 
Cell proliferation profiles for CF from 8 ND and 8 T2DM donors were constructed by culturing 
cells in FGM and counting cells over a 7-day period (Fig. 1C). A 3.3-fold and 2.7-fold increase 
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in cell number was demonstrated over the course of the experiment for ND and T2DM 
populations respectively (ANOVA: both P<0.001). There was no significant difference in 
proliferation rates between the two cohorts of cells (ANOVA: P=0.429) (Fig. 1C).   
 
3.3. Influence of T2DM on insulin receptor signalling 
At the molecular level, insulin resistance is attributable to defective insulin receptor signalling, in 
particular impaired phosphorylation of the insulin receptor substrate protein IRS-1 [25]. This 
results in selective down-regulation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway, 
but not the extracellular signal-regulated kinase (ERK) mitogen-activated kinase pathway in 
skeletal muscle [26]. We measured activity of these pathways in CF from ND and T2DM donors 
following insulin treatment for 5-60 min. ND cells exhibited relatively high basal levels of Akt 
and ERK phosphorylation and insulin was unable to stimulate them further (Fig. 2). In contrast, 
in T2DM cells basal levels of Akt and ERK phosphorylation appeared to be lower than in ND 
cells, although this was not statistically significant. Moreover, the response to insulin was more 
apparent in T2DM cells with marked increases in Akt and ERK phosphorylation maintained for 
at least 60 min and 30 min respectively (Fig. 2).  
 
3.4. Influence of T2DM on basal and IL-ĮLQGXFHGJHQHH[SUHVVLRQ 
IL-1D is a proinflammatory cytokine whose levels are increased in the heart early after 
myocardial infarction and can modulate many cellular functions of CF that are pertinent to 
cardiac remodelling [27]. Using real-time RT-PCR we assessed the influence of T2DM on 
mRNA expression of several pertinent genes at basal level and following treatment with IL-1D. 
Specifically, we investigated expression of the proLQIODPPDWRU\F\WRNLQHV,/ȕ,/ and IL8, the 
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myofibroblast differentiation marker ACTA2 (the gene encoding D-smooth muscle actin 
[DSMA]), type I collagen (COL1A1) and the matrix metalloproteinases MMP2 and MMP3; 
genes that we have previously studied in this cell type [23,28-30].  
 IL-1D VXEVWDQWLDOO\LQFUHDVHGH[SUHVVLRQRI,/ȕ,/DQG,/ mRNA after 6 h in both 
T2DM and ND cells, and levels remained significantly elevated after 24 h (Fig. 3A-C). Although 
there was a suggestion of reduced IL6 and IL8 expression after 6 h, there was no statistically 
significant difference in the overall profile of proinflammatory cytokine expression between 
T2DM and ND cells (Fig. 3A-C). 
 The mean basal ACTA2 mRNA expression in T2DM cells was 80% higher than that of ND 
cells (Fig. 3D), however the high level of variation in the T2DM data meant that this difference 
was not statistically significant (P=0.492). IL-1D treatment reduced ACTA2 expression after 24 
h, in agreement with our recent report [30], but there was no difference between T2DM and ND 
CF (Fig. 3D). 
  Basal and IL-1D-induced MMP2 mRNA expression was similar in CF from ND and T2DM 
donors (Fig. 3E). In contrast, there was a trend towards reduced basal mRNA expression of 
MMP3 in T2DM compared with ND cells (0.004±0.001% GAPDH vs. 0.026±0.013% GAPDH 
respectively, P=0.055) (Fig. 3F). Moreover, the extent of IL-1D-stimulated MMP3 mRNA 
expression in T2DM CF was generally lower than that of controls over the time course studied 
(P=0.079) (Fig. 3F).  
 The major difference we observed was at the level of COL1A1 gene expression (Fig. 4A). 
Basal COL1A1 mRNA expression in T2DM CF was 2-fold higher than that observed in ND 
cells (131.4±26.8% GAPDH compared with 66.2±7.4% GAPDH respectively, P=0.033). IL-1D 
treatment suppressed COL1A1 expression in both T2DM and ND cells. Remarkably though, 
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even 24 h after IL-1D incubation, COL1A1 mRNA levels in T2DM cells remained greater than 
those in untreated ND cells (Fig. 4A). This result was confirmed at the protein level by Western 
blotting (Fig. 4B). There was a larger degree of variation in collagen I protein expression in the 
T2DM cells and the median basal expression level in T2DM cells was 2.6-fold greater than that 
of ND cells (P=0.05; Fig. 4B). 
 
4. Discussion 
In this study we investigated whether T2DM could confer inherent changes in human CF 
function at the levels of morphology, proliferation, insulin signalling and mRNA expression of 
key remodelling genes. Our principal finding was that COL1A1 mRNA levels were elevated in 
CF derived from T2DM donors compared with cells from ND donors; a change reflected at the 
protein level. In addition, there was a trend towards reduced MMP3 expression in these T2DM 
cells. Together these changes suggest that CF from T2DM patients adopt a pro-fibrotic 
phenotype, in keeping with the increased fibrosis evident in diabetic hearts [6]. CF from T2DM 
donors had a greater variation in cell size than ND cells and an overall trend towards increased 
cell area, although cell proliferation rates were similar for the two cohorts. Finally, whilst basal 
Akt and ERK phosphorylation were lower in T2DM cells, they showed generally increased 
responses to insulin. 
 Currently there is relatively little known about whether diabetes can directly modulate CF 
function. Although there are several reports describing in vitro effects of glucose concentration 
on CF function [13-16], the diabetic milieu is far more complex than hyperglycaemia alone and 
other factors such as hyperlipidaemia, advanced glycation end products, oxidative stress, 
proinflammatory cytokines, adipokines and profibrotic cytokines must also be considered [31]. 
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Using fibroblasts cultured from the hearts of Zucker diabetic rats, a laboratory model of T2DM, 
it was recently demonstrated that diabetic cells adopt a more myofibroblast-like phenotype 
compared with cells derived from lean control hearts [17]. Changes were relatively small, but 
included increased contractile behaviour, increased DSMA and type I collagen expression and 
increased cell proliferation in the diabetic cells [17]. Very recently, in a study using a murine 
model of T2DM (db/db mouse), CF derived from db/db hearts were shown to have elevated 
expression of several pro-fibrotic markers (type I collagen, PAI-1, TGF-ȕ, TIMP-2) compared 
with cells derived from db/wt littermates [18]. In contrast to previous reports, altering glucose 
concentration in the culture medium had no modulatory effects on expression of any of the 
proteins studied [18]. It is worth noting that the Zucker diabetic rat and db/db mouse models, 
both of which result from a mutation in the leptin receptor, are unlikely to reflect all the changes 
observed in human T2DM. Indeed, several differences have been noted between the cardiac 
phenotype of these models compared with that observed in diabetic patients [32]. 
 Despite these inter-species differences, our data add to an emerging consensus that T2DM 
can drive CF to adopt a pro-fibrotic phenotype (increased type I collagen expression) that is 
maintained throughout long-term in vitro culture i.e. in the absence of the initiating diabetic 
stimulus. Increased expression of ECM proteins, including type I and III collagen, is observed in 
a range of organs affected by diabetes including the heart, kidney, liver and pancreas 
[6].Whether the changes we observed were due to increased differentiation of cells to a 
myofibroblast phenotype, as has been proposed [17], is not clear at this stage as increases in 
DSMA expression (a marker of the myofibroblast phenotype) observed in diabetic rat CF [17] 
were not observed in diabetic mouse CF [18]. In our human cells, although mean ACTA2 
mRNA expression in T2DM-derived CF was higher than that of ND donors, the variation 
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between patients meant that this was not statistically significant. Similarly, we observed a trend 
towards increased cell size in T2DM cells compared with ND controls, but again the variation in 
the data for the T2DM cells meant that these changes were not statistically significant.  
 In addition to upregulation of COL1A1 mRNA expression, we observed a trend towards 
decreased MMP3 mRNA expression in T2DM cells. CF express several members of the MMP 
family [33], and importantly MMP3 can stimulate a cascade of ECM degradation by cleaving 
and activating other downstream MMPs [34]. Therefore decreased MMP3 expression in T2DM 
CF may indicate a broader reduction in downstream MMP activity which, in combination with 
increased collagen expression, would predict T2DM CF activity that favours ECM deposition.  
 Despite the heightened inflammatory state that is associated with T2DM [2], CF from T2DM 
donors had a similar profile of proinflammatory cytokine expression compared to ND controls. 
This may indicate that fibroblasts are not the major source of increased inflammatory molecules 
in T2DM and that other cell types, such as monocytes, are more important.  
 Our data revealed that T2DM CF exhibit similar proliferation rates to ND cells, which 
contrasts with previous studies using CF from rat models of Type 1 [35] and Type 2 [17] 
diabetes. Such discrepancies are likely to be multi-factorial and include inter-species variation, 
differences in duration of hyperglycaemia or age differences. Previous studies have reported that 
high glucose concentrations increase the proliferation rate of human atrial CF [13] which, when 
taken in combination with our findings, suggests that glucose can acutely increase cell 
proliferation, but that these changes may not be maintained in the absence of the initiating 
stimulus.  
 Basal phosphorylation levels of Akt and ERK were generally lower in CF from T2DM 
donors compared with ND cells, and T2DM cells appeared more responsive upon addition of 
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insulin, although none of these differences between the two cohorts were statistically significant. 
These results were surprising given previous reports that T2DM impairs PI3K/Akt signalling 
without affecting ERK signalling [25,26]. However, most of the evidence for this comes from 
studies on skeletal muscle and it is unknown whether similar mechanisms occur in CF. 
Interestingly, increased IRS-PI3K-Akt signalling has been reported in left ventricular biopsies 
from T2DM patients and the myocardium of ob/ob diabetic mouse hearts [36], suggesting that 
diabetes affects insulin signalling differently in diverse tissues and cells. Our data show no overt 
deficit in insulin signalling (Akt or ERK) in CF derived from T2DM donors.       
 We have previously reported that human vascular smooth muscle cells cultured from T2DM 
donors exhibit altered morphology, increased migration rate and decreased proliferation 
compared with cells from ND donors [37]. The maintenance of phenotypic features throughout 
long-term cell culture is likely to be indicative of epigenetic mechanisms that confer persistent 
changes in cellular function. There is increasing evidence that such epigenetic factors, including 
specific microRNAs, contribute to the pathogenesis of diabetic cardiomyopathy [38]. Further 
investigations are needed to determine whether diabetes stimulates epigenetic modification of CF 
that drives the pro-fibrotic phenotype. 
 
5. Study limitations 
Our study has a number of important limitations that should be noted. Firstly, as this was not a 
prospective study, only limited clinical and demographic information was available on the 
patient donors i.e. age, gender, diabetic status and diabetes therapy.  T2DM is associated with a 
higher prevalence of coronary artery disease, heart failure and atrial fibrillation, and all of these 
confounding variables could potentially contribute to the differences we observed. However, it is 
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worth noting that all of the donors in the study (both ND and T2DM) had coronary artery disease 
and were undergoing elective coronary artery bypass graft surgery. Therefore the presence or 
absence of diabetes was the sole known discriminator between the two cohorts. A larger study 
would be needed to evaluate the impact of other co-morbidities in this regard. Although it would 
have been informative to have a further control group of donors without coronary artery disease, 
ethical constraints prevented us from obtaining cardiac biopsies from healthy individuals. 
 Diabetic cardiomyopathy is often characterised by changes in ventricular remodelling, so our 
use of atrial fibroblasts rather than ventricular fibroblasts could also be viewed as a shortcoming. 
However, the atria also undergo remodelling in T2DM patients and so our findings may also be 
of relevance to T2DM-associated atrial remodelling.  
 Finally, the size of our study cohort was limited due to restricted availability of donor tissue 
and cells. Although we were able to use cells from a total of 26 donors, we could not perform all 
assays on all cell populations. 
 Despite these limitations, a major strength of our study was the use of CF derived from 
human heart tissue from multiple diabetic and non-diabetic patients. Our data therefore support a 
role for T2DM underlying the differential responses of the fibroblasts.  
  
6. Conclusion 
CF derived from T2DM individuals express inherently higher levels of type I collagen compared 
with cells from individuals without diabetes; differences that are maintained throughout long-
term cell culture. These findings may help to explain the augmented cardiac fibrosis observed in 
diabetic patients.    
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Figure Legends 
Fig. 1. Influence of T2DM on cell size and proliferation. (A) Representative 
photomicrographs of CF cultured from non-diabetic (ND) or T2DM donors, showing traced cell 
outlines. Scale bar = 100 µm. (B) Outlines of 50 cells from each of 10 ND and 10 T2DM 
populations were traced and mean cell areas calculated. Box depicts 25th-75th interquartile range, 
whiskers indicate full range and horizontal line is median. (C) Cells from 8 ND donors (filled 
circles) or 8 T2DM donors (open squares) were plated at 1x104 cell/well in full growth medium 
and cell proliferation measured by counting cells over a 7-day period. 2-way ANOVA: P<0.001 
for effect of time, P=0.429 for effect of diabetic status. 
 
Fig. 2. Influence of T2DM on insulin-induced Akt and ERK phosphorylation. Cells cultured 
from 5 non-diabetic donors (filled circles) and 5 T2DM donors (open squares) were treated with 
100 nM insulin for 5-60 min prior to quantification of phospho-Akt (left panel) and phospho-
ERK (right panel) by Western blotting. Pooled densitometry results (mean ± SEM; n=5) are 
expressed relative to loading control (Ctrl) that was added to every gel. Molecular weights in 
kDa are shown to the right of the blots.  
 
Fig. 3. Influence of T2DM on mRNA expression levels of remodelling genes. Cells cultured 
from 6 ND donors (filled circles) and 6 T2DM donors (open squares) were treated with 10 ng/ml 
IL-ĮIRU-KEHIRUHPHDVXULQJ,/ȕ(A), IL6 (B), IL8 (C), ACTA2 (D), MMP2 (E) and 
MMP3 (F) mRNA levels by real time RT-PCR. Results are expressed as % GAPDH mRNA 
levels. P values indicate influence of diabetic status on mRNA expression across all time points 
(2-way ANOVA). *P<0.05 for comparison between ND and T2DM data at a particular time 
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point (Holm-6LGDN¶VSRVW-hoc test); all others non-significant.  
 
Fig. 4. Influence of T2DM on type I collagen mRNA and protein expression. (A) Cells 
cultured from 6 ND donors (filled circles) and 6 T2DM donors (open squares) were treated with 
10 ng/ml IL-ĮIRU-24 h before measuring COL1A1 mRNA levels by real time RT-PCR. 
Results are expressed as % GAPDH mRNA levels. P values indicate influence of diabetic status 
on mRNA expression across all time points (2-way ANOVA). *P<0.05 for comparison between 
ND and T2DM data at a particular time point (Holm-6LGDN¶VSRVW-hoc test). (B) Control samples 
from signalling experiments were analysed for expression of COL1A1 by Western blotting. 
Expression of E-actin was used as a loading control. Each lane of the gel represents cells from a 
different patient, grouped according to diabetic status. Scatter plot (with horizontal line 
representing median) depicts densitometry data obtained from the 5 ND donors and 5 T2DM 
donors normalised WRȕ-actin levels. 
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